Dr Miroslav Ravic
MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.
Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.
MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.
MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.
Dr Michael Roberts
Synpromics is a life science company focused on synthetic biology. Our core proprietary technology enables the design of optimized Synthetic Promoters to more effectively and efficiently regulate gene expression throughout biotechnology applications. Via product-development and distribution partnerships, Synpromics will commercially apply our novel promoters to enhance and expedite life science R&D, improve biology-based production processes, advance agricultural biotech and progress personalized medicine.
SynpromicsChief Executive Officer
Mr Dave Roberts
Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling.
Selcia drug discovery provides integrated drug discovery services to support academics, institutions, biotech and pharma companies. Selcia assist in grant applications; execute the medicinal chemistry to deliver the best drug candidates, provide supporting project management and primary pharmacology, to ensure project success.
Selcia radiolabelling specialises in 14C GMP radiolabelling and produces 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, microdosing, research and regulatory studies; and environmental fate studies.
The purity and structure of our products are assured by our internal MHRA GLP accredited analytical department with 500MHz, 400MHz & 300MHz NMRs, mass spec and separation specialists. The group are experts in problem resolution to ensure projects meet agreed milestones.
Areas of Expertise:
- Medicinal chemistry: Small molecules, macrocycles, natural product chemistry
- Disease expertise: Anti-infectives, inflammation, CNS, pain, metabolic
- Target classes: GPCRs, ion channels, enzymes, isomerases
- 14C Custom Radiosynthesis
- GMP Radiolabelled API for Clinical Trials
- GLP/GMP Analytics – GLP NMR
- Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds
Selcia LtdBD Director Radiochemistry
Dr Matthew Roe
Crescendo has developed a unique transgenic mouse which generates fully human VH single domain antibody fragments in the absence of contaminating murine light chains.
VH are the smallest, most robust antibody fragments with advantages for engineering of bispecific and multivalent products, tissue and tumour penetration, topical delivery and simple manufacture.
Crescendo is applying the platform to a pipeline focused on inflammation and oncology, and topical delivery.